SMAD family member 6Genealiases: AOVD2 · HsT17432 · MADH6 · MADH7
Q-omics provides the consensus-scored SMAD6 profile across patient tissues and cancer cell-line models. SMAD6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SMAD6 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SMAD6 RNA expression shows 18,001 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, HNSC, and KIRP as cancer lineages where SMAD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMAD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMAD6 survival associations across molecular data types. SMAD6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMAD6 RNA expression–survival associations across cancer types. High SMAD6 expression shows unfavorable associations in PAAD and COAD, but favorable associations in KIRC, HNSC, UCEC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SMAD6 RNA expression.
This table summarizes SMAD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SMAD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMAD6 shows lower tumor expression in LUAD, KICH, KIRC and LUSC and higher tumor expression in HNSC and COAD. The HNSC box plot shows higher SMAD6 RNA expression in tumor versus normal tissue (log2 FC = +0.631, t-test p < 0.001).
This table shows molecular features associated with SMAD6 in patient tissues and cancer cell lines. In patient samples, SMAD6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SMAD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
